JP2016507581A5 - - Google Patents

Download PDF

Info

Publication number
JP2016507581A5
JP2016507581A5 JP2015557539A JP2015557539A JP2016507581A5 JP 2016507581 A5 JP2016507581 A5 JP 2016507581A5 JP 2015557539 A JP2015557539 A JP 2015557539A JP 2015557539 A JP2015557539 A JP 2015557539A JP 2016507581 A5 JP2016507581 A5 JP 2016507581A5
Authority
JP
Japan
Prior art keywords
alkyl
group
pharmaceutically acceptable
halo
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015557539A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016507581A (ja
JP6505023B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/058840 external-priority patent/WO2014128585A1/en
Publication of JP2016507581A publication Critical patent/JP2016507581A/ja
Publication of JP2016507581A5 publication Critical patent/JP2016507581A5/ja
Application granted granted Critical
Publication of JP6505023B2 publication Critical patent/JP6505023B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015557539A 2013-02-19 2014-02-06 Cnsおよび他の障害を治療するための、pde4アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物 Active JP6505023B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361766268P 2013-02-19 2013-02-19
US61/766,268 2013-02-19
PCT/IB2014/058840 WO2014128585A1 (en) 2013-02-19 2014-02-06 Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018231938A Division JP2019069966A (ja) 2013-02-19 2018-12-11 Cnsおよび他の障害を治療するための、pde4アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物

Publications (3)

Publication Number Publication Date
JP2016507581A JP2016507581A (ja) 2016-03-10
JP2016507581A5 true JP2016507581A5 (US06894165-20050517-C00155.png) 2017-03-02
JP6505023B2 JP6505023B2 (ja) 2019-04-24

Family

ID=50151342

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015557539A Active JP6505023B2 (ja) 2013-02-19 2014-02-06 Cnsおよび他の障害を治療するための、pde4アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物
JP2018231938A Pending JP2019069966A (ja) 2013-02-19 2018-12-11 Cnsおよび他の障害を治療するための、pde4アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018231938A Pending JP2019069966A (ja) 2013-02-19 2018-12-11 Cnsおよび他の障害を治療するための、pde4アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物

Country Status (30)

Country Link
US (2) US9120788B2 (US06894165-20050517-C00155.png)
EP (1) EP2958915B1 (US06894165-20050517-C00155.png)
JP (2) JP6505023B2 (US06894165-20050517-C00155.png)
KR (1) KR20150119370A (US06894165-20050517-C00155.png)
CN (1) CN105121439A (US06894165-20050517-C00155.png)
AP (1) AP2015008663A0 (US06894165-20050517-C00155.png)
AR (1) AR094702A1 (US06894165-20050517-C00155.png)
AU (1) AU2014220351A1 (US06894165-20050517-C00155.png)
BR (1) BR112015019276A2 (US06894165-20050517-C00155.png)
CA (1) CA2900302C (US06894165-20050517-C00155.png)
CL (1) CL2015002222A1 (US06894165-20050517-C00155.png)
CR (1) CR20150425A (US06894165-20050517-C00155.png)
CU (1) CU20150082A7 (US06894165-20050517-C00155.png)
DO (1) DOP2015000201A (US06894165-20050517-C00155.png)
EA (1) EA201591360A1 (US06894165-20050517-C00155.png)
EC (1) ECSP15035278A (US06894165-20050517-C00155.png)
ES (1) ES2638850T3 (US06894165-20050517-C00155.png)
HK (1) HK1217945A1 (US06894165-20050517-C00155.png)
IL (1) IL240672A0 (US06894165-20050517-C00155.png)
MA (1) MA38333A1 (US06894165-20050517-C00155.png)
MD (1) MD20150071A2 (US06894165-20050517-C00155.png)
MX (1) MX2015010714A (US06894165-20050517-C00155.png)
NI (1) NI201500112A (US06894165-20050517-C00155.png)
PE (1) PE20151332A1 (US06894165-20050517-C00155.png)
PH (1) PH12015501755A1 (US06894165-20050517-C00155.png)
SG (1) SG11201505878UA (US06894165-20050517-C00155.png)
TN (1) TN2015000347A1 (US06894165-20050517-C00155.png)
TW (1) TW201443048A (US06894165-20050517-C00155.png)
UY (1) UY35333A (US06894165-20050517-C00155.png)
WO (1) WO2014128585A1 (US06894165-20050517-C00155.png)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20151332A1 (es) 2013-02-19 2015-09-20 Pfizer Compuestos de azabencimidazol
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
DK3177624T3 (da) 2014-08-06 2019-07-01 Pfizer Imidazopyridazinforbindelser
BR112017023038A2 (pt) 2015-04-29 2018-07-03 Janssen Pharmaceutica Nv imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa
MA41988B1 (fr) * 2015-04-29 2021-03-31 Janssen Pharmaceutica Nv Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa
MX2017013877A (es) 2015-04-29 2018-08-15 Janssen Pharmaceutica Nv Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
US10604484B2 (en) 2015-04-29 2020-03-31 Janssen Pharmaceutica Nv Indolone compounds and their use as AMPA receptor modulators
CN107787322B (zh) 2015-06-17 2023-07-07 辉瑞大药厂 三环化合物以及它们作为磷酸二酯酶抑制剂的用途
AR107099A1 (es) * 2015-12-22 2018-03-21 Gruenenthal Gmbh Compuestos espiro-[indolin heterocicloalcano] como inhibidores de la fosfodiesterasa
AU2017223132B2 (en) * 2016-02-23 2019-12-05 Pfizer Inc. 6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
EP3502099B1 (en) * 2016-08-22 2020-12-09 Medshine Discovery Inc. Cyclic compound acting as pde4 inhibitor
WO2018234354A1 (en) 2017-06-20 2018-12-27 Grünenthal GmbH NOVEL SUBSTITUTED 3-INDOLE AND 3-INDAZOLE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS
WO2018234353A1 (en) 2017-06-20 2018-12-27 Grünenthal GmbH NOVEL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE
EP3643711A1 (en) 2018-10-24 2020-04-29 Bayer Animal Health GmbH New anthelmintic compounds
CN115361866A (zh) * 2020-03-31 2022-11-18 株式会社Lg化学 用于保护胰岛移植的组合物
CN112390750B (zh) * 2020-11-11 2022-03-01 常州大学 作为选择性磷酸二酯酶2抑制剂的喹啉酮类化合物及其制备方法

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
US5750349A (en) 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
JPH08295667A (ja) * 1995-04-27 1996-11-12 Takeda Chem Ind Ltd 複素環化合物、その製造法および剤
JPH08295687A (ja) * 1995-04-28 1996-11-12 Ube Ind Ltd 無水シトラコン酸の製造法
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
EP2305709A1 (en) 1997-04-09 2011-04-06 Intellect Neurosciences, Inc. Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods for use thereof
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
JP2004509059A (ja) * 1999-06-03 2004-03-25 アボット・ラボラトリーズ 細胞接着抑制性抗炎症化合物
SK18942001A3 (sk) 1999-06-28 2002-10-08 Janssen Pharmaceutica N. V. Inhibítory replikácie respiračného syncytiálneho vírusu
DE60118521T2 (de) 2000-01-07 2006-10-12 Universitaire Instelling Antwerpen Purin derivate, ihre herstellung und verwendung
DK1481992T3 (en) 2000-02-24 2017-01-30 Washington Univ St Louis Humanized antibodies which sequester amyloid beta peptide
CN1173975C (zh) 2000-04-27 2004-11-03 山之内制药株式会社 咪唑并吡啶衍生物
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
WO2002042429A2 (en) 2000-11-03 2002-05-30 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
GB0115181D0 (en) 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use
WO2003000697A1 (fr) 2001-06-22 2003-01-03 Takeda Chemical Industries, Ltd. Derive de furo-isoquinoline, procede de production de ce compose et utilisation de ce compose
DE60204463T2 (de) 2001-06-27 2006-05-18 Merck Frosst Canada & Co, Kirkland Substituierte 8-Arylchinoline als PDE4-Hemmer
WO2003002511A1 (fr) 2001-06-29 2003-01-09 Nikken Chemicals Co., Ltd. Derive de cycloalcenone
WO2003008396A1 (fr) 2001-07-16 2003-01-30 Nikken Chemicals Co., Ltd. Derive d'oxazine actif sur le plan optique
US7485639B2 (en) 2001-07-18 2009-02-03 Merck Patent Gmbh 4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1,2,4)triazin-5-one derivatives having a PDE-IV inhibiting and TNF-antagonistic effect for the treatment of cardiac diseases and allergies
WO2003008373A1 (de) 2001-07-19 2003-01-30 Merck Patent Gmbh Tyrosinhydrazide
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
TWI221838B (en) 2001-08-09 2004-10-11 Tanabe Seiyaku Co Pyrazinoisoquinoline compound or naphthalene compound
EP1285922A1 (en) 2001-08-13 2003-02-26 Warner-Lambert Company 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
FR2828693B1 (fr) 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
WO2003015789A2 (en) 2001-08-15 2003-02-27 Leo Pharma A/S A pharmaceutical composition for dermal application
JP2005501848A (ja) 2001-08-15 2005-01-20 アイコス コーポレイション 2h−フタラジン−1−オンおよびその使用方法
US20040192898A1 (en) 2001-08-17 2004-09-30 Jia Audrey Yunhua Anti-abeta antibodies
JO2311B1 (en) 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
GB0122031D0 (en) 2001-09-12 2001-10-31 Pfizer Ltd Use of pde4 inhibitors in a dry powder inhaler
DE60218497T2 (de) 2001-09-19 2007-11-08 Nycomed Gmbh Kombination eines nsaids und eines pde-4 inhibitors
BR0212582A (pt) 2001-09-19 2004-10-13 Altana Pharma Ag Combinação
WO2003035650A1 (fr) 2001-09-25 2003-05-01 Takeda Chemical Industries, Ltd. Inhibiteur d'entree
HUP0402289A2 (hu) 2001-10-02 2005-02-28 Pharmacia & Upjohn Company Gyógyhatású azabiciklusos csoporttal helyettesített kondenzált heteroaril-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
GB0123951D0 (en) 2001-10-05 2001-11-28 Glaxo Group Ltd Therapies for treating respiratory diseases
DE10150517A1 (de) 2001-10-12 2003-04-17 Merck Patent Gmbh Verwendung von Phosphodiesterase IV-Inhibitoren
DE60233884D1 (de) 2001-10-16 2009-11-12 Memory Pharmaceutical Corp 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidon-derivate als pde-4-hemmer zur behandlung von neurologischen syndromen
US7241890B2 (en) 2001-10-30 2007-07-10 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
SK1862004A3 (en) 2001-10-31 2004-08-03 Type 4 phosphodiesterase inhibitors and uses thereof
ATE541847T1 (de) 2001-11-01 2012-02-15 Icagen Inc Pyrazolopyrimidine als natriumkanalblocker
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
CA2465746C (en) 2001-11-05 2011-09-06 Merck Patent Gesellschaft Mit Beschraenkter Haftung Hydrazono-malonitriles
US20030092706A1 (en) 2001-11-09 2003-05-15 Johannes Barsig Combination
IS7221A (is) 2001-11-15 2004-04-15 Memory Pharmaceuticals Corporation Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og aðferðir til notkunar þeirra
FR2832711B1 (fr) 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
US20050101000A1 (en) 2002-12-11 2005-05-12 Isis Pharmaceuticals Inc. Modulation of phosphodiesterase 4B expression
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
JP2006519762A (ja) 2002-10-09 2006-08-31 ライナット ニューロサイエンス コーポレイション アミロイドβペプチド及びその組成物に対する抗体を使用して、アルツハイマー病を治療する方法
WO2004042390A2 (en) 2002-11-08 2004-05-21 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b)
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
WO2004089471A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
JP2006522747A (ja) 2003-04-11 2006-10-05 ノボ ノルディスク アクティーゼルスカブ 縮合1,2,4−トリアゾールの薬学的使用
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
CA2528652A1 (en) 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist
CA2530081A1 (en) 2003-07-01 2005-01-13 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
FR2857966A1 (fr) 2003-07-24 2005-01-28 Aventis Pharma Sa Produits aryl-heteroaromatiques, compositions les contenant et utilisation
US20050020587A1 (en) 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
GB0322722D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
GB0322726D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
CN101579529A (zh) 2003-09-29 2009-11-18 托皮根药品公司 治疗包括炎症状况的疾病的寡核苷酸组合物和方法
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
WO2005066151A2 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2005080361A1 (en) 2004-02-02 2005-09-01 Pfizer Products Inc. Histamine-3 receptor modulators
CN101031293A (zh) 2004-05-06 2007-09-05 普莱希科公司 Pde4b抑制剂及其应用
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
AP2007003890A0 (en) 2004-07-30 2007-02-28 Rinat Neuroscience Corp Antibodies directed against amy-loid-beta peptide and methods using same
AU2005279795A1 (en) 2004-09-03 2006-03-09 Plexxikon, Inc. Bicyclic heteroaryl PDE4B inhibitors
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
WO2006034312A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coa-desaturase (scd)
EP1809294A4 (en) 2004-09-21 2008-08-06 Synta Pharmaceuticals Corp COMPOUNDS AGAINST INFLAMMATION AND IMMUNE-RELEVANT USES
FR2877015B1 (fr) 2004-10-21 2007-10-26 Commissariat Energie Atomique Revetement nanostructure et procede de revetement.
DE102004054634A1 (de) * 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
WO2006069081A2 (en) 2004-12-22 2006-06-29 Washington University In St. Louis USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
EP1849465A4 (en) 2005-02-18 2008-12-24 Takeda Pharmaceutical AGENT FOR CONTROLLING THE FUNCTION OF THE GPR34 RECEPTOR
GB0503955D0 (en) 2005-02-25 2005-04-06 Glaxo Group Ltd Novel compounds
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
BRPI0609225A2 (pt) 2005-05-12 2010-03-09 Pfizer formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas
CA2603830A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc PYRIDINE [2,3-B] PYRAZINONES
WO2006126082A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
US7812040B2 (en) 2005-06-22 2010-10-12 Pfizer Inc. Histamine-3 receptor antagonists
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
CA2624625A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
EP2007749A2 (en) 2006-03-13 2008-12-31 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
GB0605462D0 (en) 2006-03-17 2006-04-26 Glaxo Group Ltd Novel compounds
WO2007122466A1 (en) 2006-04-21 2007-11-01 Pfizer Products Inc. Pyridine[3,4-b]pyrazinones
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
US8138205B2 (en) 2006-07-07 2012-03-20 Kalypsys, Inc. Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
US20090291950A1 (en) 2006-07-07 2009-11-26 Kalypsys, Inc. Bicyclic heteroaryl inhibitors of pde4
RU2450004C2 (ru) 2006-08-04 2012-05-10 Мерц Фарма Гмбх Унд Ко. Кгаа Замещенные пиразолопиримидины, способ их получения и их применение в качестве лекарственного средства
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
WO2008033739A2 (en) * 2006-09-12 2008-03-20 Neurogen Corporation Benzimidazole carboxamide derivatives
WO2008045664A2 (en) 2006-10-06 2008-04-17 Kalypsys, Inc. Heterocyclic pde4 inhibitors as antiinflammatory agents
US20100105729A1 (en) 2006-10-06 2010-04-29 Kalypsys, Inc. Aryl-substituted heterocyclic pde4 inhibitors as anti-inflammatory agents
US20080102475A1 (en) 2006-10-13 2008-05-01 Zhengyan Kan Alternatively spliced isoform of phosphodiesterase 4B (PDE4B)
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
WO2008056176A1 (en) 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines as phosphodiesterase inhibitors
CA2676456C (en) 2007-01-22 2012-03-27 Pfizer Products Inc. Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
JP2010535773A (ja) 2007-08-10 2010-11-25 グラクソスミスクライン エルエルシー ウイルス感染を治療するための窒素含有二環式化学物質
AU2008286946B2 (en) 2007-08-10 2013-11-21 H. Lundbeck A/S Heteroaryl amide analogues
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2009108551A2 (en) 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
GB2461702A (en) 2008-07-08 2010-01-13 Dyson Technology Ltd Hand drying apparatus
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
US8853125B2 (en) 2008-09-24 2014-10-07 Basf Se Pyrazole compounds for controlling invertebrate pests
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
PL2408446T3 (pl) 2009-03-20 2020-03-31 Hg&H Pharmaceuticals (Pty) Limited Zastosowanie kompozycji farmaceutycznych zawierających mesembrenon
MX2012004990A (es) 2009-10-30 2012-06-12 Janssen Pharmaceutica Nv Deribados de imidazo [1,2-b] pirimideazina y su uso como inhibidores de la enzima fosfodiesterasa 10.
KR20120098745A (ko) 2009-11-25 2012-09-05 메르츠 파마 게엠베하 운트 코. 카가아 치환된 피라졸로피리미딘의 결정질 형태
AR079451A1 (es) 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
CA2792339A1 (en) 2010-03-23 2011-09-29 High Point Pharmaceuticals, Llc Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
EP2569285A1 (en) 2010-05-10 2013-03-20 Gilead Sciences, Inc. Bifunctional quinoline derivatives
AR081377A1 (es) 2010-05-10 2012-08-29 Gilead Sciences Inc Compuestos de pirazolopiridina bifuncionales
US8609669B2 (en) 2010-11-16 2013-12-17 Abbvie Inc. Potassium channel modulators
US9096605B2 (en) 2011-08-24 2015-08-04 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as PI3 kinase inhibitors
PE20151332A1 (es) * 2013-02-19 2015-09-20 Pfizer Compuestos de azabencimidazol
US9193736B2 (en) 2013-06-11 2015-11-24 Janssen Pharmaceutica, Nv PDE 10a inhibitors for the treatment of type II diabetes
GB201321734D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
CN111772834B (zh) 2014-03-21 2022-07-15 阿莱恩技术有限公司 具有弹性体的分段的正畸矫正器
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
DK3177624T3 (da) 2014-08-06 2019-07-01 Pfizer Imidazopyridazinforbindelser

Similar Documents

Publication Publication Date Title
JP2016507581A5 (US06894165-20050517-C00155.png)
JP2018519323A5 (US06894165-20050517-C00155.png)
JP2016525136A5 (US06894165-20050517-C00155.png)
EA201650029A1 (ru) Пиразолопиридины и пиразолопиримидины
JP2016512520A5 (US06894165-20050517-C00155.png)
JP2016525135A5 (US06894165-20050517-C00155.png)
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
JP2019501125A5 (US06894165-20050517-C00155.png)
WO2015108490A3 (en) Heteroaryl alkyne derivatives and uses thereof
MD4779B1 (ro) Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4
EA201001126A1 (ru) Пирролопиримидины и пирролопиридины
JP2019524883A5 (US06894165-20050517-C00155.png)
JP2016515562A5 (US06894165-20050517-C00155.png)
JP2016506960A5 (US06894165-20050517-C00155.png)
CY1119231T1 (el) Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3
JP2016532715A5 (US06894165-20050517-C00155.png)
JP2016535031A5 (US06894165-20050517-C00155.png)
JP2016540742A5 (US06894165-20050517-C00155.png)
JP2017509586A5 (US06894165-20050517-C00155.png)
JP2014525937A5 (US06894165-20050517-C00155.png)
JP2014501766A5 (US06894165-20050517-C00155.png)
JP2016518317A5 (US06894165-20050517-C00155.png)
JP2015508092A5 (US06894165-20050517-C00155.png)
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
JP2016540749A5 (US06894165-20050517-C00155.png)